Basilea starts ceftobiprole Phase III

Basilea (SWX:BSLN) and Johnson & Johnson (JNJ) started the double-blind, international Phase III STRAUSS 2 trial of ceftobiprole ( BAL5788) in 816 patients with Gram-positive and -negative complicated skin and skin structure infections (cSSSIs). The primary endpoint is clinical cure rate seven to 14 days after the end of therapy. Ceftobiprole also is in the Phase III STRAUSS trial to treat Gram-positive cSSSIs. BSLN expects data from STRAUSS in the first quarter of 2006 and from STRAUSS 2 at the end of 2006. ...